Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease

Blood

Volumn 89, Issue 3, 1997, Pages 814-822

  Yuen, Alan R ^a   Rosenberg, Saul A ^a   Hoppe, Richard T ^a   Halpern, Jerry D ^a   Horning, Sandra J ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ARTICLE; AUTOGRAFT; DRUG MEGADOSE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE;

EID: 0030942265     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.3.814     Document Type: Article

References (30)

1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478, 1992
2. Canellos GP: Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol 1:1, 1991
3. Harker WG, Kushlan P, Rosenberg SA: Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 101:440, 1984
4. Bonadonna G, Santoro A, Gianni AM, Viviani S, Siena S, Bregni M, Zucali R, Lombardi F, Bonfante V, Gianni L, Valagusa P: Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Ann Oncol 1:9, 1991
5. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ, Connors JM, O'Reilly SE, Spinelli JJ, Philips GL: High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV+/-P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451, 1995
6. Nademanee A, O'Donnell MR, Snyder DS, Scmidt GM, Parker PM, Stein AS, Smith EP, Moina A, Stepan DE, Somlo G, Margolin KA, Sniecinski I, Dagis AC, Niland J, Pezner R, Forman SJ: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 85:1381, 1995
7. Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552, 1994
8. Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP, Herzig GP, Herzig RH, Klingemann HG, LeMaistre CF, O'Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolf SN, Phillips GL: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9:1871, 1991
9. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig JP: Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086, 1989
10. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P, Cetto GL, Cimino R, Alessandrino EP, Brusamolino E, Santini G, Tura S, Mandelli F, Rizzoli V, Bernasconi C, Marmont AM: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 6:1411, 1988
11. Philip T, Dumont J, Teillet F, Maraninchi D, Gorin NC, Kuentz M, Harousseau JL, Marty M, Pinkerton R, Herve P: High-dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Br J Cancer 53:737, 1986
12. Armitage JO, Bierman PJ, Vose JM, Anderson JR, Weisenburger DD, Kessinger A, Reed EC, Vaughan WP, Coccia PF, Purtilo DT: Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 91:605, 1991
13. Jones RJ, Piantadosi S, Mann RB, Ambinder RF, Seifter EJ, Vriesendorp HM, Abeloff MD, Burns WH, May WS, Rowley SD, Vogelsang GB, Wagner JE, Wiley JM, Wingard JR, Yeager AM, Saral R, Santos GW: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8:527, 1990
14. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, Eder JP: Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J Clin Oncol 8:648, 1990
15. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137, 1993
16. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117, 1988
17. Devita V Jr, Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881, 1970
18. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139, 1982
19. Jin NR, Hill RS, Petersen FB, Buckner CD, Stewart PS, Amos D, Appelbaum FR, Clift RA, Bensinger WI, Sanders JE, Doney KC, Sullivan KM, Witherspoon RP, Deeg HJ, Storb R, Livingston R, Chard R, Thomas ED: Marrow harvesting for autologous marrow transplantation. Exp Hematol 13:879, 1985
20. Kaplan H, Meier P: Nonparametic estimation from incomplete observations. Am Stat Assoc J 53:457, 1958
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Treat Rep 50:163, 1966
22. Cox D: Regression models and life tables. J R Stat Soc (B) 34:187, 1972
23. Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761, 1979
24. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051, 1993
25. Lohri A, Barnett M, Fairey RN, O'Reilly SE, Phillips GL, Reece D, Voss N, Connors JM: Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77:2292, 1991
26. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss M, Chan KW, Phillips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide +/-cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83:1193, 1994
27. Hoppe RT, Rosenberg SA, Kaplan HS, Cox RS: Prognostic factors in pathological stage IIIA Hodgkin's disease. Cancer 46:1240, 1980
28. Klimo P, Connors J: MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174, 1985
29. Longo DL, Young RC, Hubbard SM, Wesley M, Fisher RI, Jaffe E, Berard C, DeVita V Jr: Prolonged initial remission in patients with nodular mixed lymphoma. Ann Intern Med 100:651, 1984
30. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 13:1080, 1995